MedTrace Logo

Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine

NCT01277159 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2022-04-14

Study results available
· View outcomes & findings →

Summary

Patients scheduled to go home after ankle surgery at HSS typically receive a sciatic nerve block in the popliteal fossa and oral analgesic tablets (such as Percocet). Popliteal fossa nerve blockade has reduced pain for these patients (YaDeau et al, Anesth Analg 2008;106:1916-20), but unfortunately the patients still often experience moderate to severe pain after the block wears off. The investigators wish to study two additives that may prolong the period of analgesia provided by the nerve block. The additives will be studied in the context of a standardized postoperative multimodal analgesic pathway.

Primary outcome:

Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?

Conditions

  • Patients Undergoing Ankle Surgery

Interventions

DRUG

A. Control Nerve Block. IV Dexamethasone (4 mg).

A. Control Nerve Block. IV Dexamethasone (4 mg).

DRUG

B. Nerve Block with Dexamethasone (4 mg). IV saline.

B. Nerve Block with Dexamethasone (4 mg). IV saline.

DRUG

C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)

C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)

DRUG

D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).

D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).

DRUG

E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).

E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.

Sponsors & Collaborators

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • Michael Urban · Hospital for Special Surgery, New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277159 on ClinicalTrials.gov